A prospective identification and mechanistic evaluation of clinically significant drug–drug interactions in chronic kidney disease patients using the Micromedex® database
DOI:
https://doi.org/10.18203/2320-6012.ijrms20262188Keywords:
Chronic kidney disease, Drug–drug interactions, Pharmacovigilance, Cytochrome P450, PolypharmacyAbstract
Background: Chronic kidney disease (CKD) patients are highly susceptible to drug–drug interactions (DDIs) due to polypharmacy and altered pharmacokinetics. To prospectively identify and characterize clinically significant DDIs in CKD patients using a standardized database approach.
Methods: A prospective observational study was conducted in 380 CKD patients (stages 1–5). Drug–drug interactions were identified using the Micromedex® database. Clinically significant DDIs were predefined as interactions classified as major or moderate severity or those requiring clinical intervention such as dose adjustment, monitoring, or drug avoidance. Interactions were categorized by severity and mechanism (pharmacokinetic/pharmacodynamic), including cytochrome P450 (CYP) involvement.
Results: A total of 61 clinically significant DDIs were identified, including 21 major, 28 moderate, and 12 minor interactions. Major DDIs were predominantly pharmacodynamic and associated with bleeding, nephrotoxicity, electrolyte imbalance, and cardiac conduction abnormalities. Pharmacokinetic interactions commonly involved CYP3A4, followed by CYP2D6, CYP2C9, and CYP2C19 enzymes.
Conclusion: Clinically significant DDIs are common in CKD patients and can be systematically identified using standardized tools such as Micromedex®. Most interactions are predictable and manageable through monitoring, dose adjustment, or avoidance strategies.
References
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. The Lancet. 2013;382(9888):260-72.
Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. GBD Chronic Kidney Disease Collaboration: Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(709-733):32061315.
Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-33.
Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members*. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Int Med. 2013;158(11):825-30.
Manley HJ, Cannella CA, Bailie GR, Peter WL. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis. 2005;46(4):669-80.
Harder S. Anticoagulant dosing in renal impairment. Phlebologie. 2015;44(06):316-9.
Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clinical Pharmacology & Therapeutics. 2008;83(6):898-903.
Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Therap. 2008;83(6):898-03.
Dreisbach AW, Lertora JJ. The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial. 2003;16(1):45-50.
Aronoff G. Drug prescribing in renal failure. ACP Press. 2007. Available at: https://books.google.com /books/about/Drug_Prescribing_in_Renal_Failure_5th_Ed.html?id=bH9omb-HKp4C. Accessed on 14 March 2026.
Palmer BF, Clegg DJ. Electrolyte and acid–base disturbances in patients with diabetes mellitus. N Engl J Med. 2015;373(6):548-59.
Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3):531-48.
Marquito AB, Fernandes NM, Colugnati FA, Paula RB. Identifying potential drug interactions in chronic kidney disease patients. Brazil J Nephrol. 2014;36:26-34.
Reis AM, Cassiani SH. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics (Sao Paulo). 2011;66(1):9-15.
Alomar MJ. Factors affecting the development of adverse drug reactions. Saudi Pharm J. 2014;22(2):83-94.
Nolin TD, Frye RF, Le P, Sadr H, Naud J, Leblond FA, et al. ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Society Nephrol. 2009;20(10):2269-76.
World Health Organization. Safety monitoring of medicinal products: guidelines for setting up and running a pharmacovigilance centre. Uppsala Monitoring Centre: World Health Organization. 2000. Available at: https://who-umc.org/media/1703/ 24747.pdf. Accessed on 14 March 2026.
Downloads
Published
How to Cite
Issue
Section
